# 🎯 INTEGRATION STATUS: VISUAL OVERVIEW

**Date**: October 31, 2024

---

## 📊 **SYSTEM ARCHITECTURE: WHAT'S WIRED vs. WHAT'S NOT**

```
┌─────────────────────────────────────────────────────────────┐
│                     FRONTEND LAYER                          │
├─────────────────────────────────────────────────────────────┤
│                                                             │
│  ┌──────────────────────┐        ┌──────────────────────┐  │
│  │  CoPilot UI          │        │  Myeloma Digital     │  │
│  │  ❌ NOT WIRED        │        │  Twin Page           │  │
│  │                      │        │  ❌ NOT WIRED        │  │
│  │  - No treatment      │        │                      │  │
│  │    history input     │        │  - Components built  │  │
│  │  - No provenance     │        │  - Not imported      │  │
│  │    display           │        │  - Not used          │  │
│  └──────────────────────┘        └──────────────────────┘  │
│                                                             │
│  ┌──────────────────────────────────────────────────────┐  │
│  │  Ready Components (NOT IMPORTED ANYWHERE)            │  │
│  │  ✅ TreatmentHistoryForm.jsx       (353 lines)      │  │
│  │  ✅ TreatmentLineProvenance.jsx    (289 lines)      │  │
│  │  ✅ SAETreatmentLineChips.jsx      (154 lines)      │  │
│  └──────────────────────────────────────────────────────┘  │
│                                                             │
└─────────────────────────────────────────────────────────────┘
                            │
                            │ API Calls
                            ▼
┌─────────────────────────────────────────────────────────────┐
│                     BACKEND LAYER                           │
├─────────────────────────────────────────────────────────────┤
│                                                             │
│  ┌──────────────────────────────────────────────────────┐  │
│  │  POST /api/efficacy/predict                          │  │
│  │  ✅ WIRED & WORKING                                  │  │
│  │                                                      │  │
│  │  Accepts:                                            │  │
│  │  {                                                   │  │
│  │    mutations: [...],                                 │  │
│  │    disease: "ovarian_cancer",                        │  │
│  │    model_id: "evo2_1b",                              │  │
│  │    treatment_history: {  ⚠️  Optional, not used yet │  │
│  │      current_line: 2,                                │  │
│  │      prior_therapies: ["..."]                        │  │
│  │    }                                                 │  │
│  │  }                                                   │  │
│  │                                                      │  │
│  │  Returns:                                            │  │
│  │  {                                                   │  │
│  │    drugs: [                                          │  │
│  │      {                                               │  │
│  │        name: "olaparib",                             │  │
│  │        confidence: 0.72,  ✅ Modulated               │  │
│  │        treatment_line_provenance: {  ✅ Present     │  │
│  │          current_line: 2,                            │  │
│  │          cross_resistance_risk: 0.15,                │  │
│  │          confidence_penalty: -0.08                   │  │
│  │        }                                             │  │
│  │      }                                               │  │
│  │    ]                                                 │  │
│  │  }                                                   │  │
│  └──────────────────────────────────────────────────────┘  │
│                            │                                │
│                            ▼                                │
│  ┌──────────────────────────────────────────────────────┐  │
│  │  Efficacy Orchestrator                               │  │
│  │  ✅ FULLY INTEGRATED                                 │  │
│  │                                                      │  │
│  │  - Treatment line integration: ✅ ACTIVE             │  │
│  │  - Cross-resistance map: ✅ LOADED                   │  │
│  │  - Confidence modulation: ✅ WORKING                 │  │
│  │  - SAE features: ✅ COMPUTED                         │  │
│  └──────────────────────────────────────────────────────┘  │
│                            │                                │
│                            ▼                                │
│  ┌──────────────────────────────────────────────────────┐  │
│  │  Drug Panels & Services                              │  │
│  │  ✅ PRODUCTION-READY                                 │  │
│  │                                                      │  │
│  │  - panel_config.py (475 lines, 10 drugs)            │  │
│  │  - cross_resistance_map.py (142 lines, 12 rules)    │  │
│  │  - treatment_line_integration.py (145 lines)        │  │
│  │  - 29/29 tests passing                               │  │
│  └──────────────────────────────────────────────────────┘  │
│                                                             │
└─────────────────────────────────────────────────────────────┘
```

---

## 🔴 **THE GAP: FRONTEND NOT WIRED**

### **Current User Experience**

```
┌─────────────────────────────────────────────────────┐
│  USER OPENS MYELOMA DIGITAL TWIN PAGE               │
└─────────────────────────────────────────────────────┘
              │
              ▼
┌─────────────────────────────────────────────────────┐
│  Sees:                                              │
│  - Variant input fields                             │
│  - Model selector                                   │
│  - "Run Prediction" button                          │
│                                                     │
│  MISSING:                                           │
│  ❌ No treatment history input form                 │
│  ❌ No current line selector                        │
│  ❌ No prior therapies list                         │
└─────────────────────────────────────────────────────┘
              │
              ▼ User clicks "Run Prediction"
┌─────────────────────────────────────────────────────┐
│  Backend Receives:                                  │
│  {                                                  │
│    mutations: [...],                                │
│    disease: "multiple myeloma",                     │
│    model_id: "evo2_7b",                             │
│    treatment_history: null  ⚠️  MISSING            │
│  }                                                  │
└─────────────────────────────────────────────────────┘
              │
              ▼ Backend processes with default (L1, no priors)
┌─────────────────────────────────────────────────────┐
│  Backend Returns:                                   │
│  {                                                  │
│    drugs: [                                         │
│      {                                              │
│        name: "olaparib",                            │
│        confidence: 0.80,  ⚠️  NO PENALTY APPLIED   │
│        treatment_line_provenance: null  ⚠️         │
│      }                                              │
│    ]                                                │
│  }                                                  │
└─────────────────────────────────────────────────────┘
              │
              ▼
┌─────────────────────────────────────────────────────┐
│  User Sees Results:                                 │
│  - Drug rankings                                    │
│  - Confidence scores (NOT ADJUSTED)                 │
│  - Evidence tiers                                   │
│                                                     │
│  MISSING:                                           │
│  ❌ No treatment line provenance panel              │
│  ❌ No SAE feature chips                            │
│  ❌ No cross-resistance warnings                    │
│  ❌ No confidence penalty explanation               │
└─────────────────────────────────────────────────────┘
```

### **Desired User Experience (After Wiring)**

```
┌─────────────────────────────────────────────────────┐
│  USER OPENS MYELOMA DIGITAL TWIN PAGE               │
└─────────────────────────────────────────────────────┘
              │
              ▼
┌─────────────────────────────────────────────────────┐
│  Sees:                                              │
│  ✅ Treatment History Section (NEW)                 │
│     - Current treatment line: [1] [2] [3] [4+]     │
│     - Prior therapies:                              │
│       □ carboplatin+paclitaxel                      │
│       □ olaparib                                    │
│       □ doxorubicin_liposomal                       │
│                                                     │
│  - Variant input fields                             │
│  - Model selector                                   │
│  - "Run Prediction" button                          │
└─────────────────────────────────────────────────────┘
              │
              ▼ User selects: L2, prior=[carboplatin+paclitaxel]
┌─────────────────────────────────────────────────────┐
│  Backend Receives:                                  │
│  {                                                  │
│    mutations: [...],                                │
│    disease: "ovarian_cancer",                       │
│    model_id: "evo2_1b",                             │
│    treatment_history: {  ✅ PRESENT                 │
│      current_line: 2,                               │
│      prior_therapies: ["carboplatin+paclitaxel"]    │
│    }                                                │
│  }                                                  │
└─────────────────────────────────────────────────────┘
              │
              ▼ Backend applies cross-resistance logic
┌─────────────────────────────────────────────────────┐
│  Backend Returns:                                   │
│  {                                                  │
│    drugs: [                                         │
│      {                                              │
│        name: "olaparib",                            │
│        confidence: 0.72,  ✅ PENALTY APPLIED        │
│        treatment_line_provenance: {  ✅ PRESENT    │
│          current_line: 2,                           │
│          cross_resistance_risk: 0.15,               │
│          line_appropriateness: 0.90,                │
│          confidence_penalty: -0.08,                 │
│          rationale: "DNA repair cross-resistance"   │
│        }                                            │
│      }                                              │
│    ]                                                │
│  }                                                  │
└─────────────────────────────────────────────────────┘
              │
              ▼
┌─────────────────────────────────────────────────────┐
│  User Sees Results:                                 │
│  - Drug rankings                                    │
│  - Confidence scores (ADJUSTED: 0.80 → 0.72)        │
│  - Evidence tiers                                   │
│                                                     │
│  ✅ NEW: Treatment Line Provenance Panel            │
│     ┌───────────────────────────────────────┐      │
│     │ Treatment Context                     │      │
│     │ Current Line: 2                       │      │
│     │ Prior Therapies: carboplatin+paclitax │      │
│     │ Cross-Resistance Risk: 15% (Low ⚠️)   │      │
│     │ Line Appropriateness: 90% (Good ✅)   │      │
│     │ Confidence Penalty: -8%               │      │
│     │ Rationale: DNA repair overlap between │      │
│     │ prior platinum and PARP inhibitor     │      │
│     └───────────────────────────────────────┘      │
│                                                     │
│  ✅ NEW: SAE Feature Chips                          │
│     [Line Fit: 0.90 ✅] [Cross-Res: 0.15 ⚠️]      │
│     [Sequencing: 0.75]                              │
└─────────────────────────────────────────────────────┘
```

---

## 📊 **DRUG COVERAGE: CURRENT vs. TARGET**

### **Current State (Hereditary Pathway)**

```
┌─────────────────────────────────────────────────────┐
│  CURRENT DRUG PANELS (10 drugs, 2 diseases)        │
├─────────────────────────────────────────────────────┤
│                                                     │
│  Ovarian Cancer (7 drugs)                          │
│  ├─ L1: carboplatin+paclitaxel                     │
│  ├─ L1: carboplatin+paclitaxel+bevacizumab         │
│  ├─ L1/L2: olaparib (maintenance/treatment)        │
│  ├─ L1/L2: niraparib (maintenance/treatment)       │
│  ├─ L2: gemcitabine+carboplatin                    │
│  ├─ L2: doxorubicin_liposomal                      │
│  └─ L3: topotecan                                  │
│                                                     │
│  Breast HER2+ (3 drugs)                            │
│  ├─ L1: trastuzumab+pertuzumab+docetaxel           │
│  ├─ L2/L3: trastuzumab_deruxtecan (T-DXd)          │
│  └─ L3: tucatinib+trastuzumab+capecitabine         │
│                                                     │
│  Cross-Resistance Rules: 12 entries                │
│  ├─ DNA repair pathway (5 rules)                   │
│  ├─ HER2 pathway (4 rules)                         │
│  └─ Anthracycline class (3 rules)                  │
│                                                     │
└─────────────────────────────────────────────────────┘
```

### **Phase 1 Expansion (2-3 weeks) → 50-70 drugs**

```
┌─────────────────────────────────────────────────────┐
│  TARGET PANELS (Phase 1: 6 diseases, 50-70 drugs)  │
├─────────────────────────────────────────────────────┤
│                                                     │
│  1. Ovarian Cancer (7 drugs) ✅ COMPLETE           │
│  2. Breast HER2+ (3 drugs) ✅ COMPLETE             │
│                                                     │
│  3. Lung Cancer NSCLC (15-20 drugs) ⏳ NEXT        │
│     ├─ L1: osimertinib (EGFR+)                     │
│     ├─ L1: alectinib (ALK+)                        │
│     ├─ L1: crizotinib (ROS1+)                      │
│     ├─ L1: pembrolizumab (PD-L1 high)              │
│     ├─ L1: carboplatin+pemetrexed                  │
│     └─ L2-L4: docetaxel, ramucirumab, etc.         │
│                                                     │
│  4. Colorectal Cancer (10-15 drugs) ⏳             │
│     ├─ L1: FOLFOX                                  │
│     ├─ L1: FOLFIRI                                 │
│     ├─ L1: cetuximab (RAS wild-type)               │
│     ├─ L2: regorafenib                             │
│     └─ L2: trifluridine/tipiracil                  │
│                                                     │
│  5. Melanoma (8-10 drugs) ⏳                        │
│     ├─ L1: dabrafenib+trametinib (BRAF V600)       │
│     ├─ L1: nivolumab+ipilimumab                    │
│     ├─ L1: pembrolizumab                           │
│     └─ L2: imatinib (c-KIT+)                       │
│                                                     │
│  6. Prostate Cancer (10-12 drugs) ⏳               │
│     ├─ L1: enzalutamide                            │
│     ├─ L1: abiraterone                             │
│     ├─ L1: docetaxel                               │
│     ├─ L2: cabazitaxel                             │
│     └─ L2: radium-223                              │
│                                                     │
│  Cross-Resistance Rules: ~50-70 entries            │
│  ├─ EGFR pathway (lung)                            │
│  ├─ BRAF/MEK pathway (melanoma, CRC)               │
│  ├─ Androgen pathway (prostate)                    │
│  ├─ HER2 pathway (breast)                          │
│  └─ DNA repair (ovarian, breast, prostate)         │
│                                                     │
└─────────────────────────────────────────────────────┘
```

### **Phase 2: Database Architecture (1-2 months) → 200-300 drugs**

```
┌─────────────────────────────────────────────────────┐
│  DRUG DATABASE ARCHITECTURE                         │
├─────────────────────────────────────────────────────┤
│                                                     │
│  drug_database.json (or PostgreSQL table)          │
│  {                                                  │
│    "drugs": [                                       │
│      {                                              │
│        "id": "olaparib_001",                        │
│        "name": "olaparib",                          │
│        "class": "PARP_inhibitor",                   │
│        "mechanism": "DNA_repair_inhibition",        │
│        "approved_indications": [                    │
│          {                                          │
│            "disease": "ovarian_cancer",             │
│            "biomarker": "BRCA1/2_mutation",         │
│            "lines": [1, 2],                         │
│            "nccn_categories": {                     │
│              "1": "1",                              │
│              "2": "2A"                              │
│            }                                        │
│          },                                         │
│          {                                          │
│            "disease": "breast_cancer",              │
│            "biomarker": "BRCA1/2_germline",         │
│            "lines": [2, 3]                          │
│          }                                          │
│        ],                                           │
│        "cross_resistance": [                        │
│          "platinum_agents",                         │
│          "other_PARP_inhibitors"                    │
│        ],                                           │
│        "fda_approval_date": "2014-12-19",           │
│        "last_updated": "2024-06-15"                 │
│      }                                              │
│    ]                                                │
│  }                                                  │
│                                                     │
│  Auto-Population Logic:                            │
│  def get_panel(disease, mutations, line):          │
│      # 1. Query drugs by disease indication        │
│      # 2. Filter by biomarker match                │
│      # 3. Filter by line appropriateness           │
│      # 4. Apply cross-resistance rules             │
│      # 5. Rank by NCCN category                    │
│      return ranked_drugs                           │
│                                                     │
└─────────────────────────────────────────────────────┘
```

### **Phase 3: Guidelines Integration (3-6 months) → 500+ drugs**

```
┌─────────────────────────────────────────────────────┐
│  REAL-TIME GUIDELINES INTEGRATION                   │
├─────────────────────────────────────────────────────┤
│                                                     │
│  Data Sources:                                      │
│  ├─ NCCN Guidelines API (if available)             │
│  ├─ FDA Drug Approvals (realtime feed)             │
│  ├─ ClinicalTrials.gov (emerging therapies)        │
│  ├─ OncoKB (mutation-drug associations)            │
│  └─ CIViC (clinical interpretations)               │
│                                                     │
│  Update Pipeline:                                   │
│  ┌───────────────────────────────────────────┐     │
│  │ Daily Cron Job                            │     │
│  │ ├─ Fetch new FDA approvals                │     │
│  │ ├─ Check NCCN guideline updates           │     │
│  │ ├─ Sync OncoKB biomarker rules            │     │
│  │ └─ Update drug database                   │     │
│  └───────────────────────────────────────────┘     │
│                                                     │
│  Result: Always up-to-date drug panels             │
│                                                     │
└─────────────────────────────────────────────────────┘
```

---

## 🎬 **DEMO READINESS CHECKLIST**

### **Option 1: Full Demo (Requires Frontend Wiring) - 1-2 hours**

```
[ ] Frontend wiring complete
    [ ] Import TreatmentHistoryForm into MyelomaDigitalTwin.jsx
    [ ] Add treatment history state management
    [ ] Pass treatment_history to API payload
    [ ] Display TreatmentLineProvenance in results
    [ ] Display SAETreatmentLineChips in results

[ ] Test Ayesha's case end-to-end
    [ ] L1: No prior therapies → confidence 0.80-0.85
    [ ] L2: Post-carboplatin+paclitaxel → olaparib confidence 0.72 (-8%)
    [ ] L3: Post-olaparib → topotecan confidence 0.68 (-12%)

[ ] Demo script prepared
    [ ] Setup instructions
    [ ] Act 1: First-line (2 min)
    [ ] Act 2: Progression to L2 (3 min)
    [ ] Act 3: Third-line challenge (2 min)
```

### **Option 2: Backend-Only Demo (Ready Now) - 5 minutes**

```
[✅] Backend API working
[✅] curl commands prepared
[✅] jq formatting for output
[✅] Before/after comparison ready

Demo Flow:
1. Show L1 curl → confidence 0.80 (no penalty)
2. Show L2 curl → confidence 0.72 (-8% penalty)
3. Show provenance JSON with rationale
4. Explain clinical impact
```

**Recommended**: Do Option 2 (backend demo) NOW, then wire frontend for Option 1.

---

## 💀 **COMMANDER'S ACTION ITEMS**

### **P0: Wire Frontend (1-2 hours)**
1. Open `oncology-coPilot/oncology-frontend/src/pages/MyelomaDigitalTwin.jsx`
2. Import treatment history components
3. Add state management
4. Wire to API payload
5. Display provenance in results
6. Test with Ayesha's case

### **P1: Integrate CoPilot (30 min)**
1. Open `oncology-coPilot/oncology-frontend/src/components/CoPilot/CoPilotLogic.jsx`
2. Add treatment_history to payload generation (line 120-125)
3. Display treatment line provenance in response cards
4. Add SAE chips to evidence panel

### **P2: Expand Drug Panels (1-2 weeks)**
1. Add Lung Cancer panel (15-20 drugs)
2. Add Colorectal Cancer panel (10-15 drugs)
3. Add Melanoma panel (8-10 drugs)
4. Add Prostate Cancer panel (10-12 drugs)
5. Build cross-resistance rules for new drugs

### **P3: Sporadic Pathway (3-4 hours)**
1. TumorContext schema
2. NGS parsers (Foundation, Tempus)
3. Germline vs. somatic gating
4. Frontend germline banner + NGS upload

---

**Status**: ✅ **HEREDITARY BACKEND COMPLETE, FRONTEND READY BUT NOT WIRED**

⚔️ **STANDING BY FOR WIRING ORDERS** ⚔️


